Young T Hong1, Tonny Veenith2, Deborah Dewar3, Joanne G Outtrim2, Vaithianadan Mani2, Claire Williams2, Sally Pimlott4, Peter J A Hutchinson5, Adriana Tavares3, Roberto Canales1, Chester A Mathis6, William E Klunk7, Franklin I Aigbirhio1, Jonathan P Coles2, Jean-Claude Baron8, John D Pickard1, Tim D Fryer1, William Stewart4, David K Menon9. 1. Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, England5Department of Clinical Neurosciences, University of Cambridge, Cambridge, England. 2. Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, England. 3. Institute of Neuroscience and Psychology, University of Glasgow, Scotland. 4. University of Glasgow and Southern General Hospital, Glasgow, Scotland. 5. Department of Clinical Neurosciences, University of Cambridge, Cambridge, England. 6. Departments of Radiology and Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania. 7. Departments of Psychiatry and Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 8. Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, England5Department of Clinical Neurosciences, University of Cambridge, Cambridge, England8INSERM U894, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 9. Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, England2Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, England.
Abstract
OBJECTIVES: To image amyloid deposition in patients with traumatic brain injury (TBI) using carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET) and to validate these findings using tritium-labeled PiB ([3H]PiB) autoradiography and immunocytochemistry in autopsy-acquired tissue. DESIGN, SETTING, AND PARTICIPANTS: In vivo PET at tertiary neuroscience referral center and ex vivo immunocytochemistry of autopsy-acquired brain tissue from a neuropathology archive. [11C]PiB PET was used to image amyloid deposition in 11 controls (median [range] age, 35 [24-60] years) and in 15 patients (median [range] age, 33 [21-50] years) between 1 and 361 days after a TBI. [3H]PiB autoradiography and immunocytochemistry for β-amyloid (Aβ) and β-amyloid precursor protein in brain tissue were obtained from separate cohorts of 16 patients (median [range] age, 46 [21-70] years) who died between 3 hours and 56 days after a TBI and 7 controls (median [range] age, 61 [29-71] years) who died of other causes. MAIN OUTCOMES AND MEASURES: We quantified the [11C]PiB distribution volume ratio and standardized uptake value ratio in PET images. The distribution volume ratio and the standardized uptake value ratio were measured in cortical gray matter, white matter, and multiple cortical and white matter regions of interest, as well as in striatal and thalamic regions of interest. We examined [3H]PiB binding and Aβ and β-amyloid precursor protein immunocytochemistry in autopsy-acquired brain tissue. RESULTS: Compared with the controls, the patients with TBI showed significantly increased [11C]PiB distribution volume ratios in cortical gray matter and the striatum (corrected P < .05 for both), but not in the thalamus or white matter. Increases in [11C]PiB distribution volume ratios in patients with TBI were seen across most cortical subregions, were replicated using comparisons of standardized uptake value ratios, and could not be accounted for by methodological confounders. Autoradiography revealed [3H]PiB binding in neocortical gray matter, in regions where amyloid deposition was demonstrated by immunocytochemistry; white matter showed Aβ and β-amyloid precursor protein by immunocytochemistry, but no [3H]PiB binding. No plaque-associated amyloid immunoreactivity or [3H]PiB binding was seen in cerebellar gray matter in autopsy-acquired tissue from either controls or patients with TBI, although 1 sample of cerebellar tissue from a patient with TBI showed amyloid angiopathy in meningeal vessels. CONCLUSIONS AND RELEVANCE: [11C]PiB shows increased binding following TBI. The specificity of this binding is supported by neocortical [3H]PiB binding in regions of amyloid deposition in the postmortem tissue of patients with TBI. [11C]PiB PET could be valuable in imaging amyloid deposition following TBI.
OBJECTIVES: To image amyloid deposition in patients with traumatic brain injury (TBI) using carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET) and to validate these findings using tritium-labeled PiB ([3H]PiB) autoradiography and immunocytochemistry in autopsy-acquired tissue. DESIGN, SETTING, AND PARTICIPANTS: In vivo PET at tertiary neuroscience referral center and ex vivo immunocytochemistry of autopsy-acquired brain tissue from a neuropathology archive. [11C]PiB PET was used to image amyloid deposition in 11 controls (median [range] age, 35 [24-60] years) and in 15 patients (median [range] age, 33 [21-50] years) between 1 and 361 days after a TBI. [3H]PiB autoradiography and immunocytochemistry for β-amyloid (Aβ) and β-amyloid precursor protein in brain tissue were obtained from separate cohorts of 16 patients (median [range] age, 46 [21-70] years) who died between 3 hours and 56 days after a TBI and 7 controls (median [range] age, 61 [29-71] years) who died of other causes. MAIN OUTCOMES AND MEASURES: We quantified the [11C]PiB distribution volume ratio and standardized uptake value ratio in PET images. The distribution volume ratio and the standardized uptake value ratio were measured in cortical gray matter, white matter, and multiple cortical and white matter regions of interest, as well as in striatal and thalamic regions of interest. We examined [3H]PiB binding and Aβ and β-amyloid precursor protein immunocytochemistry in autopsy-acquired brain tissue. RESULTS: Compared with the controls, the patients with TBI showed significantly increased [11C]PiB distribution volume ratios in cortical gray matter and the striatum (corrected P < .05 for both), but not in the thalamus or white matter. Increases in [11C]PiB distribution volume ratios in patients with TBI were seen across most cortical subregions, were replicated using comparisons of standardized uptake value ratios, and could not be accounted for by methodological confounders. Autoradiography revealed [3H]PiB binding in neocortical gray matter, in regions where amyloid deposition was demonstrated by immunocytochemistry; white matter showed Aβ and β-amyloid precursor protein by immunocytochemistry, but no [3H]PiB binding. No plaque-associated amyloid immunoreactivity or [3H]PiB binding was seen in cerebellar gray matter in autopsy-acquired tissue from either controls or patients with TBI, although 1 sample of cerebellar tissue from a patient with TBI showed amyloid angiopathy in meningeal vessels. CONCLUSIONS AND RELEVANCE: [11C]PiB shows increased binding following TBI. The specificity of this binding is supported by neocortical [3H]PiB binding in regions of amyloid deposition in the postmortem tissue of patients with TBI. [11C]PiB PET could be valuable in imaging amyloid deposition following TBI.
Authors: Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Ronald L Hamilton; Chester A Mathis; William R Paljug; Manik L Debnath; Anne D Cohen; Katsuyoshi Mizukami; Steven T DeKosky; Oscar L Lopez; William E Klunk Journal: Acta Neuropathol Date: 2012-01-24 Impact factor: 17.088
Authors: M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun Journal: Ann Neurol Date: 2010-01 Impact factor: 10.422
Authors: S M Gentleman; B D Greenberg; M J Savage; M Noori; S J Newman; G W Roberts; W S Griffin; D I Graham Journal: Neuroreport Date: 1997-04-14 Impact factor: 1.837
Authors: G W Roberts; S M Gentleman; A Lynch; L Murray; M Landon; D I Graham Journal: J Neurol Neurosurg Psychiatry Date: 1994-04 Impact factor: 10.154
Authors: Xiao-Han Chen; Robert Siman; Akira Iwata; David F Meaney; John Q Trojanowski; Douglas H Smith Journal: Am J Pathol Date: 2004-08 Impact factor: 4.307
Authors: William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky Journal: J Neurosci Date: 2007-06-06 Impact factor: 6.167
Authors: Raquel C Gardner; Katherine L Possin; Christopher P Hess; Eric J Huang; Lea T Grinberg; Amber L Nolan; Brendan I Cohn-Sheehy; Pia M Ghosh; Serggio Lanata; Jennifer Merrilees; Joel H Kramer; Mitchel S Berger; Bruce L Miller; Kristine Yaffe; Gil D Rabinovici Journal: Neurol Clin Pract Date: 2015-08
Authors: Elisabeth A Wilde; Sylvain Bouix; David F Tate; Alexander P Lin; Mary R Newsome; Brian A Taylor; James R Stone; James Montier; Samuel E Gandy; Brian Biekman; Martha E Shenton; Gerald York Journal: Brain Imaging Behav Date: 2015-09 Impact factor: 3.978
Authors: Andrea L C Schneider; Elizabeth Selvin; Menglu Liang; Lawrence Latour; L Christine Turtzo; Silvia Koton; Josef Coresh; Thomas Mosley; Christopher T Whitlow; Yun Zhou; Dean F Wong; Geoffrey Ling; Rebecca F Gottesman Journal: J Neurotrauma Date: 2019-05-23 Impact factor: 5.269
Authors: Franck Amyot; David B Arciniegas; Michael P Brazaitis; Kenneth C Curley; Ramon Diaz-Arrastia; Amir Gandjbakhche; Peter Herscovitch; Sidney R Hinds; Geoffrey T Manley; Anthony Pacifico; Alexander Razumovsky; Jason Riley; Wanda Salzer; Robert Shih; James G Smirniotopoulos; Derek Stocker Journal: J Neurotrauma Date: 2015-09-30 Impact factor: 5.269
Authors: Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong Journal: CNS Drugs Date: 2015-04 Impact factor: 5.749